Cargando…

Investigating the causal role of MRE11A p.E506* in breast and ovarian cancer

The nuclease MRE11A is often included in genetic test panels for hereditary breast and ovarian cancer (HBOC) due to its BRCA1-related molecular function in the DNA repair pathway. However, whether MRE11A is a true predisposition gene for HBOC is still questionable. We determined to investigate this...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elkholi, Islam E., Di Iorio, Massimo, Fahiminiya, Somayyeh, Arcand, Suzanna L., Han, HyeRim, Nogué, Clara, Behl, Supriya, Hamel, Nancy, Giroux, Sylvie, de Ladurantaye, Manon, Aleynikova, Olga, Gotlieb, Walter H., Côté, Jean-François, Rousseau, François, Tonin, Patricia N., Provencher, Diane, MesMasson, Anne-Marie, Akbari, Mohammad R., Rivera, Barbara, Foulkes, William D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844268/ https://www.ncbi.nlm.nih.gov/pubmed/33510186 http://dx.doi.org/10.1038/s41598-021-81106-w

Ejemplares similares

Germline TP53 mutational spectrum in French Canadians with breast cancer
por: Arcand, Suzanna L, et al.
Publicado: (2015)

Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent
por: Cavallone, Luca, et al.
Publicado: (2008)

Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families
por: Oros, Kathleen K, et al.
Publicado: (2006)

A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population
por: Belanger, Moria H, et al.
Publicado: (2015)

Founder BRCA1/BRCA2/PALB2 pathogenic variants in French-Canadian breast cancer cases and controls
por: Behl, Supriya, et al.
Publicado: (2020)

Novel high-grade serous epithelial ovarian cancer cell lines that reflect the molecular diversity of both the sporadic and hereditary disease
por: Fleury, Hubert, et al.
Publicado: (2015)

The Genomic Landscape of TP53 and p53 Annotated High Grade Ovarian Serous Carcinomas from a Defined Founder Population Associated with Patient Outcome
por: Wojnarowicz, Paulina M., et al.
Publicado: (2012)

Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer
por: Létourneau, Isabelle J, et al.
Publicado: (2012)

Overexpressing the CCL2 chemokine in an epithelial ovarian cancer cell line results in latency of in vivo tumourigenicity
por: Wojnarowicz, P, et al.
Publicado: (2012)

BMP-2 signaling in ovarian cancer and its association with poor prognosis
por: Le Page, Cécile, et al.
Publicado: (2009)

Chromosome 3 Anomalies Investigated by Genome Wide SNP Analysis of Benign, Low Malignant Potential and Low Grade Ovarian Serous Tumours
por: Birch, Ashley H., et al.
Publicado: (2011)

The Genetic and Molecular Analyses of RAD51C and RAD51D Identifies Rare Variants Implicated in Hereditary Ovarian Cancer from a Genetically Unique Population
por: Alenezi, Wejdan M., et al.
Publicado: (2022)

Characterization of three new serous epithelial ovarian cancer cell lines
por: Ouellet, Véronique, et al.
Publicado: (2008)

The chemiluminescence based Ziplex(® )automated workstation focus array reproduces ovarian cancer Affymetrix GeneChip(® )expression profiles
por: Quinn, Michael CJ, et al.
Publicado: (2009)

Expression of Stem Cell Markers in Preinvasive Tubal Lesions of Ovarian Carcinoma
por: Chene, G., et al.
Publicado: (2015)

Contribution of the PALB2 c.2323C>T [p.Q775X] Founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent
por: Tischkowitz, Marc, et al.
Publicado: (2013)

RARE-22. GERMLINE PATHOGENIC VARIANT c.1552G>A;p.E518K IN DGCR8 CONFERS SUSCEPTIBILITY FOR SCHWANNOMATOSIS AND THYROID TUMORS
por: Chong, Anne-Sophie, et al.
Publicado: (2020)

Case Review: Whole-Exome Sequencing Analyses Identify Carriers of a Known Likely Pathogenic Intronic BRCA1 Variant in Ovarian Cancer Cases Clinically Negative for Pathogenic BRCA1 and BRCA2 Variants
por: Alenezi, Wejdan M., et al.
Publicado: (2022)

An essential role for Ran GTPase in epithelial ovarian cancer cell survival
por: Barrès, Véronique, et al.
Publicado: (2010)

The Role of MreB, MreC and MreD in the Morphology of the Diazotrophic Filament of Anabaena sp. PCC 7120
por: Velázquez-Suárez, Cristina, et al.
Publicado: (2022)

Atypical tuberous sclerosis complex presenting as familial renal cell carcinoma with leiomyomatous stroma
por: Bah, Ismaël, et al.
Publicado: (2018)

Cumulative defects in DNA repair pathways drive the PARP inhibitor response in high-grade serous epithelial ovarian cancer cell lines
por: Fleury, Hubert, et al.
Publicado: (2016)

Influence of monolayer, spheroid, and tumor growth conditions on chromosome 3 gene expression in tumorigenic epithelial ovarian cancer cell lines
por: Cody, Neal AL, et al.
Publicado: (2008)

MreC and MreD Proteins Are Not Required for Growth of Staphylococcus aureus
por: Tavares, Andreia C., et al.
Publicado: (2015)

Ristretto MRE: A generalized multi‐shot GRE‐MRE sequence
por: Guenthner, Christian, et al.
Publicado: (2019)

Current gene panels account for nearly all homologous recombination repair-associated multiple-case breast cancer families
por: Matis, Thibaut S., et al.
Publicado: (2021)

A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene
por: Fierheller, Caitlin T., et al.
Publicado: (2021)

Modeling the Diversity of Epithelial Ovarian Cancer through Ten Novel Well Characterized Cell Lines Covering Multiple Subtypes of the Disease
por: Sauriol, Alexandre, et al.
Publicado: (2020)

MRE11 and RAD50, but not NBS1, are essential for gene targeting in the moss Physcomitrella patens
por: Kamisugi, Yasuko, et al.
Publicado: (2012)

Chemotherapy reduces PARP1 in cancers of the ovary: implications for future clinical trials involving PARP inhibitors
por: Marques, Maud, et al.
Publicado: (2015)

Gene expression profiling of primary cultures of ovarian epithelial cells identifies novel molecular classifiers of ovarian cancer
por: Le Page, C, et al.
Publicado: (2006)

Formation of Linear Amplicons with Inverted Duplications in Leishmania Requires the MRE11 Nuclease
por: Laffitte, Marie-Claude N., et al.
Publicado: (2014)

RAN Nucleo-Cytoplasmic Transport and Mitotic Spindle Assembly Partners XPO7 and TPX2 Are New Prognostic Biomarkers in Serous Epithelial Ovarian Cancer
por: Cáceres-Gorriti, Katia Y., et al.
Publicado: (2014)

Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome
por: Gambaro, Karen, et al.
Publicado: (2015)

Pulmonary valve papillary fibroelastoma: to PE or not to PE
por: Kirk, Frazer, et al.
Publicado: (2023)

MreC and MreD balance the interaction between the elongasome proteins PBP2 and RodA
por: Liu, Xiaolong, et al.
Publicado: (2020)

Proteomic analysis of mare follicular fluid during late follicle development
por: Fahiminiya, Somayyeh, et al.
Publicado: (2011)

Food-Grade PE Recycling: Effect of Nanoclays on the Decontamination Efficacy
por: Laridon, Yannick, et al.
Publicado: (2020)

The wall-less bacterium Spiroplasma poulsonii builds a polymeric cytoskeleton composed of interacting MreB isoforms
por: Masson, Florent, et al.
Publicado: (2021)

Ran GTPase: A Key Player in Tumor Progression and Metastasis
por: Boudhraa, Zied, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1d03e5ofr2gpoq5auj91g1hnkj